NASDAQ:ACAD
$24.61
(
2.97%
)
Friday, 2nd Jun 2023
ACADIA Pharmaceuticals Inc. Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $20.42 | $26.04 | Friday, 2nd Jun 2023 ACAD stock ended at $24.61. This is 2.97% more than the trading day before Thursday, 1st Jun 2023. During the day the stock fluctuated 2.41% from a day low at $24.03 to a day high of $24.61. |
| 90 days | $17.71 | $26.04 | |
| 52 weeks | $12.24 | $26.04 |
Historical ACADIA Pharmaceuticals Inc. prices
| Date | Open | High | Low | Close | Volume |
| 2023-06-02 | $24.10 | $24.61 | $24.03 | $24.61 | 1 088 417 |
| 2023-06-01 | $23.11 | $23.94 | $22.35 | $23.90 | 1 138 720 |
| 2023-05-31 | $23.85 | $24.76 | $23.40 | $23.50 | 1 623 912 |
| 2023-05-30 | $24.78 | $24.98 | $23.66 | $23.79 | 1 224 882 |
| 2023-05-26 | $24.68 | $24.80 | $24.35 | $24.78 | 1 006 737 |
| 2023-05-25 | $26.00 | $26.04 | $24.08 | $24.45 | 2 202 190 |
| 2023-05-24 | $25.42 | $25.66 | $25.03 | $25.65 | 1 574 718 |
| 2023-05-23 | $24.77 | $25.73 | $24.66 | $25.54 | 1 722 212 |
| 2023-05-22 | $24.32 | $24.85 | $24.00 | $24.80 | 1 468 793 |
| 2023-05-19 | $23.52 | $24.32 | $23.48 | $24.31 | 1 748 592 |
| 2023-05-18 | $22.50 | $23.23 | $22.40 | $23.20 | 1 516 078 |
| 2023-05-17 | $21.99 | $22.78 | $22.04 | $22.68 | 1 146 611 |
| 2023-05-16 | $21.79 | $22.04 | $21.59 | $21.88 | 1 001 619 |
| 2023-05-15 | $21.55 | $22.15 | $21.47 | $22.12 | 820 368 |
| 2023-05-12 | $21.35 | $21.53 | $21.14 | $21.47 | 895 206 |
| 2023-05-11 | $21.63 | $21.70 | $21.19 | $21.34 | 926 280 |
| 2023-05-10 | $21.71 | $21.91 | $21.34 | $21.65 | 1 144 064 |
| 2023-05-09 | $21.59 | $21.70 | $20.42 | $21.43 | 1 763 445 |
| 2023-05-08 | $22.07 | $22.12 | $21.40 | $21.55 | 2 045 044 |
| 2023-05-05 | $21.66 | $22.04 | $21.25 | $21.93 | 1 114 990 |
| 2023-05-04 | $21.06 | $21.69 | $20.63 | $21.55 | 1 087 265 |
| 2023-05-03 | $21.46 | $21.85 | $21.08 | $21.20 | 1 584 387 |
| 2023-05-02 | $21.62 | $21.90 | $21.28 | $21.38 | 1 164 894 |
| 2023-05-01 | $21.18 | $21.86 | $21.16 | $21.75 | 1 238 505 |
| 2023-04-28 | $20.51 | $21.49 | $20.42 | $21.33 | 1 367 094 |
| 2023-04-27 | $20.39 | $20.61 | $20.14 | $20.50 | 835 390 |
| 2023-04-26 | $20.05 | $20.43 | $19.91 | $20.31 | 980 023 |
| 2023-04-25 | $20.13 | $20.30 | $19.93 | $20.11 | 748 203 |
| 2023-04-24 | $20.08 | $20.19 | $19.90 | $20.14 | 652 774 |
| 2023-04-21 | $19.92 | $20.12 | $19.71 | $20.09 | 1 007 614 |
| 2023-04-20 | $19.99 | $20.41 | $19.66 | $19.97 | 1 125 069 |
| 2023-04-19 | $19.64 | $20.17 | $19.53 | $20.02 | 1 290 399 |
| 2023-04-18 | $19.49 | $19.82 | $19.05 | $19.72 | 1 810 278 |
| 2023-04-17 | $18.13 | $19.46 | $18.08 | $19.37 | 2 192 750 |
| 2023-04-14 | $18.48 | $18.48 | $17.75 | $17.99 | 1 451 897 |
| 2023-04-13 | $18.46 | $18.88 | $18.33 | $18.52 | 1 523 702 |
| 2023-04-12 | $18.31 | $18.55 | $18.14 | $18.34 | 1 181 784 |
| 2023-04-11 | $17.78 | $18.22 | $17.78 | $18.09 | 1 691 253 |
| 2023-04-10 | $18.14 | $18.17 | $17.71 | $17.80 | 987 545 |
| 2023-04-06 | $18.16 | $18.47 | $18.12 | $18.35 | 1 266 418 |
| 2023-04-05 | $18.44 | $18.70 | $18.24 | $18.28 | 882 183 |
| 2023-04-04 | $19.03 | $19.14 | $18.20 | $18.48 | 1 365 235 |
| 2023-04-03 | $18.68 | $19.07 | $18.66 | $18.93 | 691 016 |
| 2023-03-31 | $18.89 | $19.10 | $18.65 | $18.82 | 878 723 |
| 2023-03-30 | $19.10 | $19.10 | $18.41 | $18.70 | 1 495 375 |
| 2023-03-29 | $18.51 | $18.99 | $18.39 | $18.98 | 1 127 137 |
| 2023-03-28 | $18.53 | $18.71 | $18.26 | $18.43 | 772 353 |
| 2023-03-27 | $18.42 | $18.72 | $18.16 | $18.60 | 1 018 229 |
| 2023-03-24 | $18.21 | $18.31 | $17.93 | $18.24 | 1 408 499 |
| 2023-03-23 | $18.72 | $18.85 | $18.11 | $18.32 | 1 155 399 |
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psych... ACAD Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
